MedTrace Logo

Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)

NCT07381205 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2026-03-11

No results posted yet for this study

Summary

The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underreported complication of Allogeneic Stem Cell Transplant (SCT). The main question it aims to answer is:

What is the incidence of TA-TMA in adults undergoing SCT? How does TA-TMA diagnosis impact survival and other outcomes? Patients undergoing SCT will be eligible for this study, which will consist of collection of biological samples and standard clinical follow up.

Conditions

  • Transplant Associated Microangiopathy TAM
  • Transplant Complication

Sponsors & Collaborators

  • BMS Foundation

    collaborator UNKNOWN

  • Viracor Eurofins

    collaborator UNKNOWN

  • Manuel Ricardo Espinoza-Gutarra

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-10-31
Completion
2028-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07381205 on ClinicalTrials.gov